The Commercialization Story

You built the science. Here's how it becomes a business.

Every life sciences company that makes it through commercialization passes through the same six chapters — whether it's a genomics platform's first enterprise logo or a metabolic drug program's first payer conversation. Here's where you are, and here's what comes next.

Day one
You built something real. The science works. The platform works. The early believers are convinced.
Six months in
You're still explaining what you do in every meeting — because there's no repeatable way to say it.
The pattern
No pipeline you'd bet on. No CRM with real data in it. No named path to your next five accounts. Every deal closes by force of personality, not by a system anyone else could run.
The question
Investors keep asking about go-to-market. You keep answering with a plan instead of a motion.
The turn
This isn't a science problem. It's a commercialization problem — and it has a shape. This is where Stacks Advisory enters.
The Story

Six chapters. Read the one you're in.

Each chapter is a phase your company either has behind it, is living in right now, or hasn't reached yet. Find yours — then see what closes the gap to the next one.

1
Diagnose
2
Design
3
Validate
4
Launch
5
Realize
6
Embed & Scale
Chapter One · Diagnose

Where growth is actually blocked

You're here if: you have customers, or real interest, but no system that predicts the next one.

Before any strategy, we map what you're actually working with — not just the commercial gaps, but the technical reality underneath them. Your CRM, or the spreadsheet standing in for one. Your data architecture. The pipeline you actually have versus the one in the board deck. This is the chapter where the vague feeling that something is broken gets a name.

Commercial infrastructure auditTech stack mappingPipeline quality reviewICP definition
Chapter Two · Design

Building the commercial engine

You're here if: you know the problem, but don't yet have a plan that survives contact with a real buyer.

Not "biopharma companies in the US" — named organizations, named decision-makers, named buying contexts. This chapter turns your science into an argument a non-scientist signs off on: the plan for how you win customers, the competitive landscape, the account list with names on it.

GTM thesisNamed account prioritizationScientific-to-commercial messagingCompetitive landscape
Chapter Three · Validate

Proving the market will actually buy

You're here if: the plan looks right on paper, but nothing has been tested against a real conversation yet.

Pilot outreach to a handful of accounts. Objection mapping. This is the cheapest chapter to get wrong on purpose — it's far better to find where the plan breaks here than three months into a full launch.

Pilot outreach sequencesEarly discovery callsObjection mappingPartner discovery
Chapter Four · Launch

The revenue engine turns on

You're here if: the plan is validated, and now it has to run at volume — not as a series of one-off favors.

BD outreach live. CRM operational with real pipeline data in it. Key accounts engaged, not just identified. This is the chapter most fractional advisors have already handed you a deck and left. We're still in the room.

Pioneer program executionLOI negotiationCRM activationPartner pipeline
Chapter Five · Realize

Becoming the reference

You're here if: you've closed accounts, but haven't yet turned them into the reason the next five close faster.

Every closed deal should generate the next three. This is where case studies, reference accounts, and the standardization case convert your early wins from proof-of-concept into inevitability.

Account closingCase study developmentStandardization business caseReference account program
Chapter Six · Embed & Scale

The company that runs without you

You're here if: revenue is real, but it still depends entirely on you personally to keep moving.

The playbook is documented. The CRM runs on your team's rhythm, not ours. Territory model, quota framework, and reporting layer are in place — infrastructure that started as separate parts is now connected end to end. That's the point it stops being a set of tools and starts functioning as your commercial operating system: the layer that keeps running, compounding, and adapting after the engagement ends. That's the actual finish line.

Commercial playbookCRM handoffQuota and territory modelReporting layer
Your Environment Determines the Detail

Same six chapters. Different execution for every stack.

Every engagement adapts to your actual environment — not a generic template. The sequencer you run, the CRM you use, and the LIMS you're on define what each chapter looks like in practice.

🗄
Contact & Pipeline Management
Where do your contacts and accounts currently live? CRM architecture and workflow design adapts entirely to your existing or target system.
HubSpot · Salesforce · Dynamics 365 · Siebel · Spreadsheet · No system yet
Impacts: CRM Architecture, Pipeline Stage Design, Outreach Automation
🧬
Sequencing Platform
If your platform touches genomics, the instrument type defines the data format, integration approach, and commercial narrative for the buyer.
Illumina NovaSeq/NextSeq · PacBio HiFi · Oxford Nanopore · Sanger · BGI/DNBSEQ
Impacts: Platform GTM Strategy, Scientific Messaging, Integration Narrative
🏭
LIMS / Lab Informatics
Your laboratory information management system determines data architecture, integration complexity, and regulatory compliance posture.
LabVantage · STARLIMS · LabWare · L7 ESP · Custom · None yet
Impacts: Data Integration Map, Regulated Market Entry
🤝
Partner & Channel Environment
Selling direct, through CROs and CDMOs, via academic medical centers, or through a platform partner? The channel defines the BD motion entirely.
Direct enterprise · CRO/CDMO · Academic/AMC · Technology partner · Distribution
Impacts: Pioneer Program, Channel Map, Partnership Playbook
📋
Regulatory Posture
Pre-clinical research tools and regulated IVDs have completely different commercial motions, buyer personas, and procurement pathways.
RUO · IVD/510(k) · LDT/CLIA · CGT/ATMP · GxP/Validated
Impacts: Regulated Market Entry, Messaging Architecture, Pricing Design
📊
Company Stage & Funding
The right commercial build for a pre-seed company and a Series B are not the same. Scope, velocity, and infrastructure priority all adapt to stage.
Pre-seed · Seed · Series A · Series B · Growth/PE-backed
Impacts: Engagement model, scope sizing, board narrative
🔒 What Comes Next

The full catalog is built for qualified engagements.

The six chapters above are your front door. Behind it: 84 indexed services across 4 commercial pillars, environment-specific SOW templates, a live services navigator, and the order form — built for clients who are ready to move.

🧬
Services Navigator
5-step guided cascade: your role → your objective → your outcome → your engagement model → matched services from the live catalog.
✓ Public — no login required
📋
Full Service Catalog (84 services)
All 84 indexed capabilities across Commercial Architecture, Strategic BD, GTM Strategy, and Revenue Acceleration.
🔒 Available post-intake
📄
Environment-Specific SOW
Statement of Work template that adapts to your CRM, sequencing platform, LIMS, channel, and regulatory context.
🔒 Available post-intake
💰
Order Form with Pricing
Benchmarked flat-rate pricing across all 4 engagement models and à la carte services — with market validation footnotes.
🔒 Available post-intake